Centaurus Therapeutics

Centaurus Biopharma is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule and biologic therapies for oncology and metabolic diseases. The company leverages a proprietary structure-based drug discovery platform to design highly selective inhibitors targeting validated pathways such as FGFR, EGFR, and PARP. Centaurus has established a robust pipeline with multiple programs in clinical development, including next-generation kinase inhibitors and antibody-drug conjugates. By combining deep expertise in medicinal chemistry with advanced structural biology, the company aims to address significant unmet medical needs in global cancer care.